Orlistat
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Orlistat: From Obesity to Hypervitaminosis
One-Sentence Summary
Orlistat is a gastric and pancreatic lipase inhibitor originally used to treat obesity, including monogenic obesity. The TxGNN model predicts it may be effective for hypervitaminosis, but no clinical trials and no publications were found in the data compiled for this report. The prediction rests on model output and pharmacological reasoning alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Obesity disorder, monogenic obesity (the approved-indication text in the India licence records is blank) |
| Predicted New Indication | Hypervitaminosis |
| TxGNN Prediction Score | 0.9942 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data from the source database is not available. Based on known pharmacology, orlistat inhibits gastric and pancreatic lipases and reduces dietary fat absorption by roughly 30%. This is how it helps with weight loss in obesity.
The link to the new indication is indirect. Fat-soluble vitamins (A, D, E, K) are absorbed together with dietary fat. Less fat absorption could therefore lower their uptake, which is a plausible way of reducing vitamin burden in hypervitaminosis, especially for vitamins A and D.
This reasoning has important limits:
- It is inferred from pharmacology only. No study in the compiled data tests orlistat as a treatment for vitamin excess.
- Reduced absorption of fat-soluble vitamins is a known adverse effect of orlistat in its approved use, not a recognised benefit.
- Hypervitaminosis from supplement overuse is normally managed by stopping the supplement, so the case for adding a drug is unclear.
- The high TxGNN score (0.9942) is a computational prediction, not clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Twenty valid single-ingredient registrations exist in India. Five are listed below. All are oral forms, and no approved-indication text is recorded for them.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 87617 | Finostat 60mg Capsule | Strip of 10 capsules | Cubit Healthcare |
| 108993 | Ishape 60mg Capsule | Strip of 10 capsules | Primus Pharmaceuticals |
| 108568 | Ishape 120mg Capsule | Strip of 10 capsules | Primus Pharmaceuticals |
| 232244 | Ultislim 120mg Tablet | Strip of 10 tablets | Akumentis Healthcare Ltd |
| 167365 | Orli-Misia 120mg Tablet | Strip of 10 tablets | Concord Drugs Ltd |
Safety Considerations
- Contraindications flagged in the knowledge graph (drug-disease relationships, not label text): liver failure, primary hyperoxaluria, anorexia nervosa, bulimia nervosa, vitamin deficiency disorder, cholestasis, benign recurrent intrahepatic cholestasis, familial intrahepatic cholestasis, drug-induced liver injury.
- The flag for vitamin deficiency disorder is directly relevant here. Orlistat can reduce absorption of fat-soluble vitamins, so using it in a vitamin-excess setting carries a risk of overshooting into deficiency.
- Drug Interactions: 314 interactions are recorded. Examples include:
- Moderate: abacavir, lamivudine, emtricitabine, atazanavir, acarbose, albiglutide, alogliptin, canagliflozin, metformin, chlorpropamide, amiodarone, cannabidiol, clofarabine, brentuximab vedotin, asparaginase products, calaspargase pegol.
- Minor: cholecalciferol, calcifediol, calcitriol.
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score and a pharmacological inference, with no clinical trials or publications. The proposed mechanism is also the cause of a known adverse effect of orlistat, and hypervitaminosis already has a simple management route (stopping the supplement).
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulator’s records
- Detailed mechanism-of-action data from DrugBank
- A literature and trial search for orlistat in vitamin A or D excess, including case reports
- Evidence that orlistat adds benefit over stopping the supplement, and a clear target population
- A safety plan addressing vitamin deficiency risk, liver and cholestasis contraindications, and interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.